Target intelligence / Profile preview

Dietary starch and other carbohydrates (CHO) (CHO)

Target
CHO
Molecular classification
Carbohydrate, Polysaccharide, Oligosaccharide, Disaccharide, Monosaccharide
01

Overview

Dietary starch and other carbohydrates represent the primary macronutrient source of metabolic energy for the human body, ranging from simple monosaccharides like glucose to complex polysaccharides like starch and fiber (NIH, 2022). Upon ingestion, complex carbohydrates are hydrolyzed by digestive enzymes, including salivary and pancreatic alpha-amylase and membrane-bound intestinal alpha-glucosidases, into absorbable monosaccharides (StatPearls, 2023). While these molecules are not therapeutic targets in the traditional sense of being receptors or enzymes, they serve as the essential substrates for pharmacological interventions in metabolic diseases. Drugs such as alpha-glucosidase inhibitors are designed to interfere with the breakdown of these carbohydrates to delay glucose absorption and mitigate postprandial hyperglycemia (PubMed, 2021). Consequently, the management of carbohydrate metabolism is a central focus in the treatment of Type 2 diabetes, obesity, and metabolic syndrome (WHO, 2023).

Other names
PolysaccharidesComplex carbohydratesSugarsStarchesDietary fiberGlycans
02

Mechanism of action

Competitive inhibition of intestinal alpha-glucosidase enzymes and pancreatic alpha-amylase, which delays the hydrolysis of dietary starch and oligosaccharides into glucose, thereby slowing glucose absorption and reducing postprandial blood glucose excursions (StatPearls, 2023; PubChem, 2023).

03

Biological functions

Primary metabolic energy sourceGlycemic regulationStructural component (dietary fiber)Prebiotic substrate for gut microbiotaGlycogen storage
04

Disease associations

Diabetes mellitus type 2ObesityMetabolic syndromeGlycogen storage diseaseDental cariesNon-alcoholic fatty liver disease (NAFLD)
05

Safety considerations

Gastrointestinal distress (flatulence, diarrhea, abdominal pain)Malabsorption of complex carbohydratesHypoglycemia (when used in combination with insulin or sulfonylureas)Elevated serum transaminases (rarely associated with high-dose acarbose)
06

Interacting drugs

Acarbose

2 more in the full profile.

07

Biomarkers

Postprandial glucose (PPG) levelsGlycated hemoglobin (HbA1c)Fasting plasma glucose (FPG)Continuous glucose monitoring (CGM) profiles

Beyond the preview

Go deeper on Dietary starch and other carbohydrates (CHO) (CHO).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dietary starch and other carbohydrates (CHO) (CHO).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call